Reaching New Heights in Nuclear Medicine

Program

High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking. In addition, two of this year’s sessions will be livestreamed to a virtual audience. The 2023 meeting, with anticipated attendance of 100 participants, promises to open avenues and opportunities of collaboration on a variety of issues important to the nuclear medicine and molecular imaging community.

Over the course of four days, the High Country Nuclear Medicine Conference will offer 27 hours of content.


Click the following link to view a PDF of the 2023 HCNMC Program as of January 26, 2023.

 

Saturday, March 11, 2023

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM  Session: Alpha Therapy

The talks will discuss the current status of alpha therapy, including availability and what agents are likely to be approved in the near future.

1:00 PM – 3:00 PM  Roundtable: General Oncology

We will discuss the latest papers on FAPI, covering both diagnostic and therapeutic applications.  Other topics may be discussed, depending on participant interests.

4:00 PM – 7:30 PM  Session: Prostate Update

In this session, we will discuss the role of nuclear medicine in evaluating and treating patients with advanced prostate cancer. We will review the appropriate use criteria for PSMA PET/CTs, the use of radioligand therapy in the clinic, and the future of theranostics. We as well discuss the critical steps in opening a theranostic center.

Sunday, March 12, 2023

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM  Session: Cutting Edge Nuclear Cardiology

This session will outline the contemporary role for cardiac PET and SPECT in disease diagnosis and risk stratification. The speakers will highlight the latest advances in clinical nuclear cardiology which will enable nuclear Cardiqoilogy to retain a prominent role in the management of patients with known or suspected coronary artery disease.

1:00 PM – 3:00 PM  Roundtable: Discussing the Future of Nuclear Cardiology

During this interactive session, speakers will discuss the future landscape for nuclear Cardiology. This forward-looking session will provide an overview of emerging applications including potential future directions for cardiac PET, the important role for nuclear Cardiology in infiltrative cardiomyopathies, and novel PET radiotracers with non-coronary applications.

4:00 PM – 6:30 PM  Session: Instrumentation

We will review the latest advances in the nuclear medicine instrumentation, including total body PET, digital and other novel PET designs as well as latest generation of SPECT/CT scanners.

7:00 PM – 9:00 PM Sunday Night Dinner & Hal O’Brien Rising Star Award Ceremony. Open to all in-person attendees with meeting registration. Additional tickets available for guests. 

Monday, March 13, 2023

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM  Session: Policy and Regulatory Updates

Federal legislative and regulatory activity related to nuclear medicine remains robust, with recent significant developments such as passage of new drug pricing legislation within the Inflation Reduction Act. A number of important regulatory initiatives have been or will be underway within the Nuclear Regulatory Commission. The mid-term elections have result in split control of the Congress. This session will provide updates regarding an overview of ongoing legislative and regulatory changes impacting the nuclear medicine sector.

1:00 PM – 3:00 PM  Roundtable: Barriers to Access/Equity & Diversity in Clinical Trials/Barriers to a more diverse workforce

We will discuss current Diversity, Equity, and Inclusion activities in nuclear medicine and molecular imaging as well as possible ways to increase diversity in the nuclear medicine community.

4:00 PM – 7:30 PM  Session: Neuroimaging

In this session we will discuss the use and role of PET tracers (beta amyloid and tau) in pivotal late stage Alzheimer‘s Disease (AD) clinical trials, as well as use and development of PET tracers in non-AD neurodegenerative diseases.

Tuesday, March 14, 2023

6:30 AM – 7:00 AM Breakfast with Vendors

7:00 AM – 9:30 AM  Session: AI/Machine Learning

Latest AI developments applied to nuclear medicine will be presented with examples in nuclear cardiology including the clinical perspective, PET brain imaging, and automated segmentation of oncological images.  

2:30 PM – 3:45 PM  Roundtable: AI

4:00 PM – 7:30 PM  Session: Controversies in Thyroid Cancer Therapy

Although we have been treating thyroid cancer with I-131 for 70 years, we still cannot agree on the best way.